Summit Therapeutics Reports Phase II AK112-206 Trial Data

Created at 5 Jun · 23:59 UTC1 source

IN SHORT

Summit Therapeutics has announced data from its Phase II AK112-206 trial. The trial focused on AK112's efficacy in patients diagnosed with non-small cell lung cancer.

Who's Involved

Summit Therapeutics

Company announcing Phase II trial data

Key facts

Summit Therapeutics announced data from its Phase II AK112-206 trial.
The trial investigated AK112 in patients with non-small cell lung cancer.

Summit Therapeutics has released data from its Phase II AK112-206 clinical trial. This trial was designed to evaluate the effectiveness of AK112 in patients suffering from non-small cell lung cancer. Further details regarding the specific outcomes and implications of the data were not immediately available in the announcement.

↳ Why This Matters

The announcement of trial data is significant for Summit Therapeutics as it provides crucial information on the potential efficacy of AK112, a key drug candidate, in treating non-small cell lung cancer, which could impact the company's future development and commercialization strategies.

FREQUENTLY ASKED

Summit Therapeutics is a biopharmaceutical company focused on developing novel medicines.

AK112 is an investigational drug being tested by Summit Therapeutics.

The trial focused on non-small cell lung cancer.

What Happens Next

01Further details on the AK112-206 trial data are expected.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

CME Headlines

Amendments to the Daily Settlement Procedure Document for all 30-Year Uniform Mortgage-Backed Securities (UMBS) To-Be-Announced (TBA) Futures Contracts

Key facts

Summit Therapeutics announced data from its Phase II AK112-206 trial.

The trial investigated AK112 in patients with non-small cell lung cancer.

Summit Therapeutics Reports Phase II AK112-206 Trial Data

PiQ Daily

Key facts

Get the newsletter.

Summit Therapeutics Reports Phase II AK112-206 Trial Data

PiQ Daily

Key facts

Get the newsletter.